Atlas Trials

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Clinical trial NCT06554184 · COMPLETED

Trial details

NCT number
NCT06554184
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Start date
2024-09-03
Primary completion
2025-07-28
Enrollment
706

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.